Regeneron Pharmaceuticals Stock Forecast, Price & News

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 6 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Regeneron Pharmaceuticals saw a decline in short interest in the month of January. As of January 29th, there was short interest totaling 1,940,000 shares, a decline of 18.8% from the January 14th total of 2,390,000 shares. Based on an average daily trading volume, of 989,500 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.9% of the shares of the company are short sold.
View Regeneron Pharmaceuticals' Short Interest.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings data on Thursday, February, 4th. The biopharmaceutical company reported $9.53 earnings per share for the quarter, topping the consensus estimate of $7.11 by $2.42. The biopharmaceutical company earned $2.42 billion during the quarter, compared to analyst estimates of $2.40 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 28.97% and a net margin of 38.28%. The company's quarterly revenue was up 11.7% compared to the same quarter last year. During the same period last year, the firm posted $7.50 EPS.
View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, REGN stock has decreased by 2.5% and is now trading at $453.19.
View which stocks have been most impacted by COVID-19.

Regeneron Pharmaceuticals declared that its Board of Directors has initiated a share buyback plan on Tuesday, November 5th 2019, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.9% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its stock is undervalued.

24 brokerages have issued twelve-month price targets for Regeneron Pharmaceuticals' stock. Their forecasts range from $429.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $621.15 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals or view top-rated stocks among Wall Street analysts.

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS).
View all of REGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (10.76%), BlackRock Inc. (9.16%), Alliancebernstein L.P. (1.65%), Northern Trust Corp (1.16%), Renaissance Technologies LLC (0.85%) and Price T Rowe Associates Inc. MD (0.81%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Nuveen Asset Management LLC, First Trust Advisors LP, Renaissance Technologies LLC, Bessemer Group Inc., Voloridge Investment Management LLC, Price T Rowe Associates Inc. MD, and Northern Trust Corp. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals or view top insider-selling stocks.

REGN stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Morgan Stanley, Assenagon Asset Management S.A., Brandywine Global Investment Management LLC, Candriam Luxembourg S.C.A., NN Investment Partners Holdings N.V., Armistice Capital LLC, and Janus Henderson Group PLC.
View insider buying and selling activity for Regeneron Pharmaceuticals or or view top insider-buying stocks.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REGN stock can currently be purchased for approximately $453.19.

Regeneron Pharmaceuticals has a market capitalization of $48.55 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis.

Regeneron Pharmaceuticals employs 8,314 workers across the globe.

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, OSMR LLC, Old Saw Mill Holdings LLC, Regeneron Assurance, Regeneron Atlantic Holdings, Regeneron Belgium BVBA, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron Healthcare Solutions, Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron Spain, Regeneron UK Limited, and Rockwood Road Holdings LLC.

Regeneron Pharmaceuticals was founded in 1988.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]